Top 25 Companies in Global Immune Repertoire Sequencing Market: Market Research Report (2026–2035)

Introduction

The global immune repertoire sequencing market focuses on advanced genomic technologies used to analyze the diversity and complexity of immune cells, particularly T-cell receptors (TCR) and B-cell receptors (BCR). The sequencing techniques provide essential information to researchers who study how the immune system functions and track how diseases advance and assess how well treatments work. The medical field uses these technologies in three main areas which include cancer immunotherapy and vaccine development and autoimmune disease research. The market is experiencing strong growth because next-generation sequencing (NGS) technologies will provide improved accuracy together with faster results and cost-effective solutions. The market expansion is driven by two factors which include rising investments in biotechnology and increasing demand for personalized targeted therapies. The immune repertoire sequencing market is experiencing fast growth because government initiatives support genomic research and global healthcare spending continues to rise.

In 2025, Oxford Nanopore Technologies extended its partnership with 10x Genomics after both companies proved that Chromium GEM-X chemistries work with V14 sequencing to deliver better and more affordable single-cell testing and enhanced genomic data results.

 

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the global immune repertoire sequencing market.

 

Market Segmentation

Global Immune Repertoire Sequencing Market Size, Share & Industry Analysis, By Type (T-Cell Receptor Sequencing, B-Cell Receptor Sequencing), By Application (Oncology, Infectious Diseases, Autoimmune Disorders), By End-Use (Hospitals, Research Institutes, Biotechnology Companies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 2026–2035

Global Immune Repertoire Sequencing Market Size & Statistics

 

• The Market size of global immune repertoire sequencing was estimated to be worth USD 0.38 billion in 2025.
• The Market is Going to Expand at a CAGR of 9.9% between 2026 and 2035.
• The Size of global immune repertoire sequencing market is anticipated to reach USD 0.98 billion by 2035.
• North America is expected to generate the fastest demand during the forecast period in the global immune repertoire sequencing market.
• Asia Pacific is expected to grow the largest during the forecast period in the global immune repertoire sequencing market.

 

 

Regional growth and demand

 

North America is expected to generate fastest demand during the forecast period in the immune repertoire sequencing market. The North America market is expanding because leading biotechnology companies establish operations in the area and precision medicine investments continue to grow. The region benefits from government support through funding which advances both immunology and cancer research initiatives. The need for personalized medical solutions along with sophisticated diagnostic equipment drives market growth.

 

Asia-Pacific is expected to grow the largest during the forecast period in the global immune repertoire sequencing market. The Asia-Pacific region will expansion occurs in China India and Japan. Rising awareness about genomic research and improving healthcare infrastructure are key growth drivers. Government initiatives supporting biotechnology innovation and increasing demand for advanced diagnostic solutions are further accelerating market growth.

 

 

Top 10 trends in the Global Immune Repertoire Sequencing Market

• Rising Demand for Personalized Medicine
• Growth in Cancer Immunotherapy Research
• Increasing Adoption of Next-Generation Sequencing (NGS)
• Expansion in Infectious Disease Research
• Growing Focus on Autoimmune Disorders
• Advancements in Bioinformatics Tools
• Increasing Research Funding and Investments
• Integration of AI in Genomic Analysis
• Rising Demand for Early Disease Detection
• Expansion of Biotechnology Industry

 

• Rising Demand for Personalized Medicine
  Personalized medicine is transforming healthcare through its ability to deliver customized treatments which match a person's specific genetic makeup. The process of immune repertoire sequencing helps scientists discover distinct immune responses which physicians use to create specific treatment plans. The system provides superior treatment result predictions while minimizing harmful effects. The rising occurrence of chronic illnesses and cancer cases creates a greater demand for personalized treatment methods. Healthcare organizations implement sophisticated genomic technologies to enhance their patient treatment methods and medical judgment processes. The global growth of precision medicine awareness and accessibility has led to increased demand for immune repertoire sequencing technologies which researchers and clinicians use in their work.

 

• Growth in Cancer Immunotherapy Research
  Cancer immunotherapy has become the main treatment method which uses the body's immune system to combat cancer. Researchers use immune repertoire sequencing to study T-cell and B-cell responses which helps them create successful immunotherapies. The system functions as an essential tool which identifies biomarkers and tracks treatment progress. The rising global cancer rates have led to more funding for immunotherapy research and clinical testing. Research organizations and pharmaceutical companies are developing new treatments which include CAR-T cell therapy. The increasing interest in immunotherapy research creates a strong need for immune sequencing technologies which scientists use in oncology studies.

 

• Increasing Adoption of Next-Generation Sequencing (NGS)
  Next-generation sequencing (NGS) technologies have transformed genomic research because they provide researchers with the ability to conduct high-throughput sequencing at reduced costs. In immune repertoire sequencing, NGS enables researchers to study different immune cell types with precise measurements. The technology delivers faster results while it enhances data quality and provides researchers with the ability to conduct large-scale studies and clinical research. The development of new sequencing platforms together with bioinformatics tools results in better performance improvements and lower operational expenses. The growing use of NGS-based solutions by laboratories and healthcare providers leads to higher accessibility for immune sequencing which results in market expansion and broader adoption across various fields including oncology and infectious diseases.

 

• Expansion in Infectious Disease Research
  Researchers now use immune repertoire sequencing techniques more frequently because they need to study and manage infectious diseases. Scientists use this technology to investigate how the immune system defends against viral and bacterial infections. The system provides essential support for developing vaccines and tracking disease outbreaks and studying how the immune system remembers past infections. The COVID-19 pandemic demonstrated how vital advanced genomic technologies are for monitoring diseases and responding to outbreaks. Governments and research organizations are investing heavily in infectious disease research to improve global health preparedness. The growing demand for immune sequencing technologies together with this development supports research progress in both immunology and public health.

 

• Growing Focus on Autoimmune Disorders
  Autoimmune disorders develop when the immune system attacks healthy cells because it identifies them as foreign invaders. Researchers use immune repertoire sequencing to study T-cell and B-cell diversity which helps them understand abnormal immune responses. The research enables scientists to create diagnostic tests and targeted treatments for diseases such as rheumatoid arthritis and lupus. Researchers in the field study autoimmune conditions because they are becoming more common in all parts of the world. Healthcare providers and pharmaceutical companies are developing personalized treatment approaches which will lead to better outcomes for patients. Immune sequencing technologies have become vital research instruments which help scientists study and treat autoimmune diseases.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the global immune repertoire sequencing market.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in global immune repertoire sequencing market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 20 Companies Leading The Global Immune Repertoire Sequencing Market

1. Illumina Inc.
2. Thermo Fisher Scientific Inc.
3. QIAGEN N.V.
4. Oxford Nanopore Technologies plc
5. Pacific Biosciences of California Inc.
6. Adaptive Biotechnologies Corporation
7. 10x Genomics Inc.
8. BGI Genomics Co. Ltd.
9. Agilent Technologies Inc.
10. Roche Diagnostics
11. Bio-Rad Laboratories Inc.
12. PerkinElmer Inc.
13. Eurofins Scientific
14. CD Genomics
15. GenScript Biotech Corporation
16. Twist Bioscience Corporation
17. ArcherDX Inc.
18. Invitae Corporation
19. Personalis Inc.
20. Genoox Ltd.
21. SOPHiA GENETICS SA
22. NeoGenomics Laboratories Inc.
23. MedGenome Labs Ltd.
24. Macrogen Inc.
25. Fulgent Genetics Inc.

 

• Illumina Inc.
  Headquarters: San Diego, California, USA
  Illumina Inc. is a global leader in next-generation sequencing (NGS) technologies and plays a crucial role in the immune repertoire sequencing market. The company provides advanced sequencing platforms and reagents that enable detailed analysis of T-cell and B-cell receptors. Its technologies are widely used in cancer immunotherapy, infectious disease research, and precision medicine. Illumina’s strong focus on innovation, high-throughput sequencing, and data accuracy makes it a preferred choice among research institutions and healthcare providers. With a global presence and continuous R&D investments, the company significantly contributes to advancements in immune system analysis and genomic research.

 

• Thermo Fisher Scientific Inc.
  Headquarters: Waltham, Massachusetts, USA
  Thermo Fisher Scientific Inc. is a leading provider of scientific research products and services, including sequencing technologies and bioinformatics tools. The company supports immune repertoire sequencing through its Ion Torrent platforms and comprehensive laboratory solutions. It offers reagents, instruments, and software that help researchers analyze immune diversity and disease mechanisms. Thermo Fisher focuses on innovation and integrated solutions, enabling faster and more accurate genomic analysis. Its strong global distribution network and diverse product portfolio serve academic, clinical, and pharmaceutical sectors, making it a key player in advancing immunology research and personalized medicine worldwide.

 

• QIAGEN N.V.
  Headquarters: Hilden, Germany
  QIAGEN N.V. specializes in sample preparation, molecular diagnostics, and bioinformatics solutions that support immune repertoire sequencing workflows. The company provides technologies for extracting and analyzing genetic material, which are essential for studying immune system diversity. Its products are widely used in research, clinical diagnostics, and pharmaceutical development. QIAGEN’s bioinformatics platforms help interpret complex sequencing data, enabling better understanding of immune responses and disease progression. With a strong focus on precision and quality, the company plays a vital role in supporting genomic research and advancing applications in immunotherapy and personalized healthcare solutions globally.

 

• Oxford Nanopore Technologies plc
  Headquarters: Oxford, United Kingdom
  Oxford Nanopore Technologies plc is known for its innovative real-time sequencing technology that allows direct analysis of DNA and RNA molecules. The company’s portable and scalable sequencing platforms are widely used in immune repertoire sequencing for analyzing long-read sequences of TCR and BCR genes. Its technology provides deeper insights into immune diversity and complex genetic variations. Oxford Nanopore focuses on accessibility, flexibility, and rapid data generation, making sequencing more efficient and cost-effective. Continuous advancements and collaborations with biotechnology companies strengthen its role in expanding genomic research and improving applications in immunology and precision medicine.

 

• Pacific Biosciences of California Inc.
  Headquarters: Oxford, United Kingdom
  Pacific Biosciences of California Inc., commonly known as PacBio, specializes in long-read sequencing technologies that are highly valuable for immune repertoire analysis. Its platforms provide highly accurate sequencing of complex genomic regions, including full-length immune receptor sequences. This enables better understanding of immune diversity and genetic variations. PacBio’s technologies are widely used in research related to cancer, infectious diseases, and immunology. The company focuses on delivering high-quality data and advanced sequencing solutions that improve research outcomes. Its strong emphasis on innovation and precision positions it as a key contributor to the growth of the immune repertoire sequencing market.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the global immune repertoire sequencing market.

 

Are you ready to discover more about the global immune repertoire sequencing market?

 

The report provides an in-depth analysis of the leading companies operating in the global immune repertoire sequencing market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Illumina Inc.

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT analysis

1. Thermo Fisher Scientific Inc.
2. QIAGEN N.V.
3. Oxford Nanopore Technologies plc
4. Pacific Biosciences of California Inc.
5. Adaptive Biotechnologies Corporation
6. 10x Genomics Inc.
7. BGI Genomics Co. Ltd.
8. Agilent Technologies Inc.
9. Others

 

Conclusion

 

The global immune repertoire sequencing market is experiencing strong growth because more people want personalized medicine and researchers study cancer immunotherapy and scientists develop methods to study infectious diseases and autoimmune diseases. Next-generation sequencing technologies which now operate at improved accuracy and scalability and generate lower costs make it possible for researchers and clinicians to conduct immune analysis throughout their work. The market is experiencing acceleration because investors are putting more money into biotechnology and genomics and governments are implementing programs that support these fields. North America will emerge as the top region for technological progress and innovation while Asia-Pacific will experience the fastest growth because of increased healthcare facilities and research expansion. Illumina Inc. and Thermo Fisher Scientific Inc. and QIAGEN N.V. will concentrate on developing new products through partnerships. The market will experience rapid growth because genomic technologies advance and more people worldwide need precision healthcare solutions.

 

Our Top Reports

Construction Punch List Software Market Size, Growth 2035
China Foodservice Market Size and Growth
Europe LPG Market Size, Shares, Trends to 2035
United Kingdom Swine Vaccines Market Forecasts to 2035
Global Vitamin C Market Size, Growth, Forecast 2035

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the global immune repertoire sequencing market.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter